Study Identifies New Genes Linked to Severe Pregnancy Sickness

Why It Matters

Doubling the known genetic contributors provides clearer biological targets, enabling precision therapies for a condition that affects 2% of pregnancies and can jeopardize maternal‑fetal health.

Key Takeaways

• Study analyzed 10,974 HG cases, 461,461 controls.
• Six new genes linked to hormone and metabolism pathways.
• TCF7L2 ties HG risk to diabetes‑related genetics.
• Findings support metformin trial to modulate GDF15.
• Genetic insights may enable personalized treatment for severe nausea.

Pulse Analysis

Hyperemesis gravidarum (HG) is the most extreme form of pregnancy‑related nausea, affecting roughly two percent of expectant mothers. Historically dismissed as a psychological issue, recent research has reframed HG as a disorder with a strong biological and genetic foundation, underscoring the risks of malnutrition for both mother and fetus. The identification of the hormone‑encoding gene GDF15 as a central driver marked a turning point, but the genetic architecture remained incomplete, limiting the development of targeted therapies. Understanding the hormonal cascade also informs obstetric monitoring and nutritional support.

The new USC‑led genome‑wide association study represents the largest cohort ever assembled for HG, comparing 10,974 affected women with 461,461 controls across European, Asian, African and Latino ancestries. In addition to confirming four previously known genes, the analysis uncovered six novel loci—FSHB, TCF7L2, SLITRK1, SYN3, IGSF11 and CDH9—many of which intersect pathways governing appetite, insulin signaling, and neural plasticity. Notably, TCF7L2, a well‑established type‑2 diabetes risk gene, links HG to glucose‑regulating mechanisms, suggesting shared metabolic vulnerabilities. These discoveries also highlight the value of multi‑ethnic cohorts in uncovering universal disease mechanisms.

These genetic insights are already shaping therapeutic strategies. By demonstrating that GDF15 sensitivity can be modulated, researchers have secured approval for a clinical trial testing metformin, a diabetes medication known to raise GDF15 levels, as a preventive measure for women with prior HG episodes. The broader gene panel also opens the door for pharmacogenomic matching of existing anti‑emetic drugs, such as Zofran, to patients most likely to respond. As precision medicine gains traction, the HG field may soon transition from symptomatic relief to disease‑modifying interventions. If successful, the metformin trial could set a precedent for repurposing metabolic drugs in obstetric care.